Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413859 | 0.78 | IDO1 (0.41) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL3306466 | 0.74 | ALDH1A1 (0.49) | CYP1A2GAASMN1; SMN2MAPT | |
| SCHEMBL6070968 | 0.70 | MAPT (0.46) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL6071098 | 0.69 | RAB9A (0.54) | CYP1A2CYP3A4GAACYP2C9SMN1; SMN2 | |
| SCHEMBL6070967 | 0.69 | L3MBTL1 (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL27962281 | 0.67 | ALDH1A1 (0.50) | CYP1A2CYP3A4GAACYP2C9CYP2C19 | |
| SCHEMBL12971503 | 0.67 | ALOX5 (0.50) | HTR1AHTR1DGAAALOX5PKM | |
| SCHEMBL6999400 | 0.67 | ALOX5 (0.54) | ALOX5PKMSMN1; SMN2MAPT | |
| SCHEMBL24704555 | 0.66 | CYP2A6 (0.46) | SMN1; SMN2TP53 | |
| SCHEMBL6071237 | 0.66 | HTR1A (0.41) | HTR1AHTR1DCASP3CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | disclosed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | HTR1A 790/4885HTR1D 1804/4885CASP3 1784/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | HTR1A 805/4885HTR1D 1632/4885CASP3 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.